CytomX Therapeutics, Inc.
Every calculator, already run for CTMX
Open the full toolkit →You have the numbers on CTMX. Get the argument.
A written report on which of these readings actually decide the outcome for CytomX Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering CTMXAnalyst Price Target Disagreement for CytomX Therapeutics, Inc.
Wall Street's bull case implies +480% from the current price; the bear case implies +117%. A 362% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CTMX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor recep…
CTMX — frequently asked
Is CTMX a buy right now?
Wall Street's consensus rating on CytomX Therapeutics, Inc. is Strong Buy across 8 analysts, with a mean price target of $12.25 (+344% vs. the current $2.76). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is CTMX's next earnings date?
CytomX Therapeutics, Inc. is next scheduled to report earnings around Nov 5, 2026. A full CTMX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for CytomX Therapeutics, Inc.?
Analysts covering CytomX Therapeutics, Inc. (CTMX) range from a bear-case target of $6.00 to a bull-case high of $16.00, with a mean consensus target of $12.25 across 8 analysts. The spread of $10.00 (362% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare CytomX Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For CytomX Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CTMX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on CytomX Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.